Antithrombotics and stent type for primary PCI.

摘要

Cardiovascular diseases are the most common cause of death worldwide, claiming 17-1 million lives a year 7.2 million of these deaths are due to coronary artery disease. Patients with coronary artery disease might present with ST-segment elevation myocardial infarction (STEMI), which is defined by characteristic signs of myocardial ischaemia and is associated with ST-segment elevation or new (or presumed-new) left-bundle branch block. The optimum treatment of STEMI has changed a lot during the past decade. The incorporation of evidence from multiple clinical trials into practice guidelines emphasises the importance of rapid reperfusion and the use of evidence-based therapies to reduce morbidity and mortality. Many studies have suggested that improving survival after STEMI is associated with timely reperfusion with primary percutaneous coronary intervention.